Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
about
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Maraviroc: a review of its use in HIV infection and beyondPre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challengesPreventing HIV infection: pre-exposure and postexposure prophylaxisCCR5 antagonism in HIV infection: current concepts and future opportunitiesAntiretroviral pharmacology in mucosal tissuesDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryDifferential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.Importance of Drug Pharmacokinetics at the Site of ActionSingle and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Advances in the Development of Microbicides for the Prevention of HIV Infection.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionQuantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesCYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Current perspectives in HIV post-exposure prophylaxis.Clinical evaluation of microbicide formulationsDarunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)Clinical use of CCR5 inhibitors in HIV and beyondTopical prophylaxis for HIV prevention in women: becoming a reality.Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesPromising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral TherapyA long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.Preexposure prophylaxis for HIV prevention.The use of preexposure treatments for HIV prophylaxisHIV prevention by oral preexposure prophylaxis.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Pharmacokinetics of antiretrovirals in mucosal tissueEtravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionMaraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
P2860
Q26777022-8F8D570B-A195-43E1-8B31-D36F75F79072Q26778504-0BA6A217-C59F-4B6D-9B11-E109252D561CQ26825641-93C36859-B120-49AC-BA43-3F650B5475C0Q26828445-669ED967-1D23-429B-A082-B1DF05FF06F1Q26865457-7C9B5818-84B8-4E55-AF41-607F43D84500Q27014675-E7AD0466-07A6-4119-A83D-71441BEBEEC8Q28081272-68A3BF18-E4FA-4759-9D87-D8319A3B3F7FQ33593633-ACEB94F7-3C6A-4B14-9019-070E52678623Q33648045-989DC0CC-8610-4BBA-B581-8AF34CB57976Q33686465-C581D8CC-3448-4835-98BC-810AC8FF3C2EQ33762924-F7BC95BD-5312-4544-BFCA-837D6561A6DCQ33769971-032E35CC-B71E-4F29-AFF0-35D1EC3796C1Q33779372-FB0A6480-B07B-4E2D-B7B9-F464DC620F91Q33821090-3926D3AF-C134-4E78-AE9C-B374FA808233Q33888718-10316971-19B6-4796-96A2-36B2877E91E3Q34030735-85DCE1CE-B061-4B84-8ACA-EE3AA67F0ED3Q34151052-1C493ECB-6141-4432-8D0E-D507A10303A6Q34360012-520ABFD0-CDA6-4894-B9BC-48283ACA9D63Q34434815-DED9D1C3-324B-4149-9222-90FCB86175F9Q34645034-C9C57CC7-BB30-4762-B861-C9A206F7A347Q34737260-07DA034E-AD62-47FE-8F0C-598807A013CFQ34834065-1A6E3969-7A6E-4591-93F9-AC1DDAF92E13Q35005146-A67C1140-9482-4150-AF7F-7CEED8A94E28Q35018145-B045983F-31A1-40E9-B4C2-23E0F486E224Q35031133-47E83D9F-4B91-4186-94EE-07E45D33A259Q35102123-32165A5C-34E5-4AC7-B3CF-A5F814422E26Q35213456-D1A0F52B-1B11-4C4E-8BC0-729C6F9FF0E0Q35432739-EF3F4D0F-A1D8-4DAF-9100-FB28839ACC57Q35619304-4F476C95-2749-4C12-A0D9-F4BD3B2DE67AQ35641179-2248FEEC-6E57-482B-8E87-41343CABA85BQ35667426-AEB2C557-630B-49E9-A0B8-89F5AE782B70Q35717688-F02F0D75-4371-4E1F-8ECF-E185BFD2C102Q35760180-FFD0FAE7-CD35-4AAF-A32E-8D1593F3B641Q35765743-2B802EFC-1C20-4318-A741-5D68AA5AB28DQ35794988-F1D8369E-29A0-4B13-884D-533A5DA043D8Q35838594-DDE919E2-5D0F-4C1C-A7DA-9CCBA40F9807Q36086387-009C1FE9-5D27-48C3-8101-1A934D3DFB10Q36143276-A63FC945-C2B4-4BDC-8D88-9CA256ABF269Q36171658-0ED59640-1972-4801-A2B3-94950B8EA943Q36430073-74EB59B1-89F1-4520-8F4D-DA7BCC8B737C
P2860
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@en
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@nl
type
label
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@en
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@nl
prefLabel
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@en
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@nl
P2093
P2860
P1476
Maraviroc concentrates in the ...... tissue of HIV-negative women.
@en
P2093
Allison L Pecha
Angela D M Kashuba
Bharat Damle
Emma Andrews
Jochen Worsley
Julie B Dumond
Kristine B Patterson
Randall Tressler
Rebecca E Werner
P2860
P304
P356
10.1097/QAI.0B013E3181AE69C5
P407
P577
2009-08-01T00:00:00Z